Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | CXCR3 | P49682 | 8/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1866120 | 1.00 | KCNH2 (0.55) | KCNH2TDP1TSHRKDM4EHTT | |
| SCHEMBL17627703 | 1.00 | KCNH2 (0.55) | KCNH2TDP1TSHRKDM4EHTT | |
| SCHEMBL17627701 | 1.00 | KCNH2 (0.55) | KCNH2TDP1TSHRKDM4EHTT | |
| SCHEMBL9723550 | 1.00 | KCNH2 (0.55) | KCNH2TDP1TSHRKDM4EHTT | |
| SCHEMBL132597 | 1.00 | KCNH2 (0.55) | KCNH2TDP1TSHRKDM4EHTT | |
| Acetic Acid SCHEMBL15140921 | 0.97 | KCNH2 (0.53) | KCNH2TDP1TSHRKDM4EHTT | |
| Acetic Acid SCHEMBL14763969 | 0.97 | KCNH2 (0.53) | KCNH2TDP1TSHRKDM4EHTT | |
| Nopol SCHEMBL7657549 | 0.95 | KCNH2 (0.51) | KCNH2TDP1TSHRKDM4EHTT | |
| SCHEMBL930939 | 0.90 | KCNH2 (0.47) | KCNH2TDP1TSHRKDM4EHTT | |
| SCHEMBL10824629 | 0.87 | KCNH2 (0.51) | KCNH2TDP1TSHRKDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1894603-B1 | Encapsulation of bulky fragrance molecules | TAKASAGO PERFUMERY CO LTD (JP) | 2014-11-19 | — | — | EP | claimed |
| WO-2025202258-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2025-10-02 | — | — | WO | disclosed |
| WO-2024175905-A1 | DIMER COMPOUNDS | Kesmalea Therapeutics Limited (GB) | 2024-08-29 | — | — | WO | disclosed |
| US-10836985-B2 | Solid composition comprising free and encapsulated fragrances | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2020-11-17 | — | — | US | disclosed |
| EP-3282003-B1 | SOLID COMPOSITION COMPRISING FREE AND ENCAPSULATED FRAGRANCES | TAKASAGO PERFUMERY CO LTD (JP) | 2020-09-02 | — | — | EP | disclosed |
| US-20200190445-A1 | SOLID COMPOSITION COMPRISING FREE AND ENCAPSULATED FRAGRANCES | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2020-06-18 | — | — | US | disclosed |
| EP-2832441-B1 | MICROCAPSULES | TAKASAGO PERFUMERY CO LTD (JP) | 2019-09-11 | — | — | EP | disclosed |
| CN-105431225-B | Microcapsule | 高砂香料工业株式会社 | 2018-06-08 | — | — | CN | disclosed |
| US-9895297-B2 | Microcapsules | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-02-20 | — | — | US | disclosed |
| WO-2018030431-A1 | SOLID COMPOSITION COMPRISING FREE AND ENCAPSULATED FRAGRANCES | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-02-15 | — | — | WO | disclosed |
| CN-105431225-A | Microcapsule | TAKASAGO PERFUMERY CO LTD | 2016-03-23 | — | — | CN | disclosed |
| WO-2015016369-A1 | MICROCAPSULES | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-02-05 | — | — | WO | disclosed |
| EP-2832441-A1 | Microcapsules | Takasago International Corporation (JP) | 2015-02-04 | — | — | EP | disclosed |
| EP-1894603-B1 | Encapsulation of bulky fragrance molecules | TAKASAGO PERFUMERY CO LTD (JP) | 2014-11-19 | — | — | EP | disclosed |
| US-8609600-B2 | Encapsulation of bulky fragrance molecules | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-12-17 | — | — | US | disclosed |
| EP-2620211-A2 | New microcapsules | Takasago International Corporation (JP) | 2013-07-31 | — | — | EP | disclosed |
| US-20110308555-A1 | PERFUME SYSTEMS | PROCTER & GAMBLE COMPANY, THE | 2011-12-22 | — | — | US | disclosed |
| US-20080176780-A1 | ENCAPSULATION OF BULKY FRAGRANCE MOLECULES | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2008-07-24 | — | — | US | disclosed |
| EP-1894603-A1 | Encapsulation of bulky fragrance molecules | Takasago International Corporation (JP) | 2008-03-05 | — | — | EP | disclosed |
| US-5175347-A | Hydogenation of a ester compound in presence of hydrogen using solid catalyst | KALI-CHEMIE PHARMA GMBH (DE) | 1992-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110308555-A1 | PERFUME SYSTEMS | TRPA1, PORCN, PLIN5 | KCNH2 1417/4885TDP1 2408/4885TSHR 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.